The aim of this paper is to estimate the return to the UK from health sector R&D drawing on the value of life methodology and the work by Murphy and Topel (2003). While acknowledging the caveats arising in making such calculations, not least the lack of consideration given to spillover effects...

Generic competition in the pharmaceutical market is an effective cost-containment mechanism that improves static efficiency and stimulates pharmaceutical innovation. There is no prior study that has empirically analysed the relative delays in adoption of generic competition. This paper aims to...

Understanding how price regulations affect the adoption of new patent-protected pharmaceutical technologies is a crucial question in designing health systems. This paper addresses this question by examining how price expectations shape the probability of launch, controlling for competition,...

A generally accepted view is that it is more efficient and ethical if global pharmaceutical prices vary according to countries? relative income. To understand manufacturers? pricing strategies, we compared average pharmaceutical prices in fourteen middle-income countries to those in three...

The TECH research network collected patient-level data on three procedures for treatment of heart attack patients, (catheterization, coronary artery by-pass grafts and percutaneous transluminal coronary angioplasty), for seventeen countries over an eighteen year period to examine the impact of...